Zomedica Pharmaceuticals Current Ratio vs. Net Asset

ZOM Stock  USD 0.15  0.01  7.14%   
Based on Zomedica Pharmaceuticals' profitability indicators, Zomedica Pharmaceuticals Corp may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in April. Profitability indicators assess Zomedica Pharmaceuticals' ability to earn profits and add value for shareholders.

Zomedica Pharmaceuticals Current Ratio

27.67

As of the 29th of March 2024, Days Of Sales Outstanding is likely to grow to 56.95, while Price To Sales Ratio is likely to drop 9.22. At this time, Zomedica Pharmaceuticals' Total Other Income Expense Net is very stable compared to the past year. As of the 29th of March 2024, Interest Income is likely to grow to about 5.9 M, though Operating Income is likely to grow to (24.1 M).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.80.83
Sufficiently Down
Slightly volatile
For Zomedica Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Zomedica Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Zomedica Pharmaceuticals Corp utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Zomedica Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Zomedica Pharmaceuticals Corp over time as well as its relative position and ranking within its peers.
  
Check out Your Current Watchlist.
Is Zomedica Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.02)
Revenue Per Share
0.024
Quarterly Revenue Growth
0.329
Return On Assets
(0.06)
Return On Equity
(0.06)
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Zomedica Pharmaceuticals Net Asset vs. Current Ratio Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Zomedica Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Zomedica Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Zomedica Pharmaceuticals Corp is rated first in current ratio category among related companies. It is rated first in net asset category among related companies making up about  6,427,816  of Net Asset per Current Ratio. At this time, Zomedica Pharmaceuticals' Current Ratio is very stable compared to the past year.. Comparative valuation analysis is a catch-all model that can be used if you cannot value Zomedica Pharmaceuticals by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Zomedica Pharmaceuticals' Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zomedica Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Zomedica Net Asset vs. Current Ratio

Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.

Zomedica Pharmaceuticals

Current Ratio

 = 

Current Asset

Current Liabilities

 = 
43.50 X
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.

Zomedica Pharmaceuticals

Net Asset

 = 

Current Market Value

-

Current Liabilities

 = 
279.61 M
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.

Zomedica Net Asset Comparison

Zomedica Pharmaceuticals is currently under evaluation in net asset category among related companies.

Zomedica Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Zomedica Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Zomedica Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Zomedica Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Zomedica Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for 2024
Accumulated Other Comprehensive Income-758.7 K-720.8 K
Operating Income-25.3 M-24.1 M
Income Before Tax-17.8 M-18.7 M
Net Loss-14.9 M-15.7 M
Net Loss-14.9 M-15.7 M
Total Other Income Expense Net2.1 M2.2 M
Net Loss-15.3 M-16.1 M
Income Tax Expense-2.1 M-2 M
Interest Income5.6 M5.9 M
Non Operating Income Net Other-142.2 K-149.3 K
Net Interest Income5.4 M5.7 M
Change To Netincome9.1 M9.5 M
Net Income Per E B T 1.01  1.03 

Zomedica Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Zomedica Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Zomedica Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Zomedica Pharmaceuticals' important profitability drivers and their relationship over time.

Use Zomedica Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zomedica Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zomedica Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Zomedica Pharmaceuticals Pair Trading

Zomedica Pharmaceuticals Corp Pair Trading Analysis

The ability to find closely correlated positions to Zomedica Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zomedica Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zomedica Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zomedica Pharmaceuticals Corp to buy it.
The correlation of Zomedica Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zomedica Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zomedica Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zomedica Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Zomedica Pharmaceuticals position

In addition to having Zomedica Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Printing and Publishing Thematic Idea Now

Printing and Publishing
Printing and Publishing Theme
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Printing and Publishing theme has 20 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Printing and Publishing Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports:
Check out Your Current Watchlist.
You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.

Complementary Tools for Zomedica Stock analysis

When running Zomedica Pharmaceuticals' price analysis, check to measure Zomedica Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zomedica Pharmaceuticals is operating at the current time. Most of Zomedica Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Zomedica Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zomedica Pharmaceuticals' price. Additionally, you may evaluate how the addition of Zomedica Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Bonds Directory
Find actively traded corporate debentures issued by US companies
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Commodity Directory
Find actively traded commodities issued by global exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
To fully project Zomedica Pharmaceuticals' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Zomedica Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Zomedica Pharmaceuticals' income statement, its balance sheet, and the statement of cash flows.
Potential Zomedica Pharmaceuticals investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Zomedica Pharmaceuticals investors may work on each financial statement separately, they are all related. The changes in Zomedica Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Zomedica Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.